c-Kit

c-Kit

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene.An essential cell surface marker for identifying specific kinds of hematopoietic (blood) progenitors in the bone marrow is called c-Kit (CD117). In addition to other cell types, hematopoietic stem cells express the cytokine receptor c-Kit on their surface. Some types of cancer may be linked to altered forms of this receptor. Stem cell factor is bound by the type III receptor tyrosine kinase known as c-Kit. To activate its intrinsic tyrosine kinase activity, c-Kit forms an adimer with stem cell factor (SCF). This adimer then phosphorylates and activates signal transduction molecules that spread the signal throughout the cell. Cell survival, division, and proliferation are affected by c-Kit signaling.

c-Kit related products

Structure Cat No. Product Name CAS No. Product Description
V77254 Anti-Mouse CD117 Antibody
V2886 Avapritinib 1703793-34-3 Avapritinib (formerly known as BLU-285; trade name Ayvakit) is an oral, potent and selective small molecule inhibitor of PDGFRα D842V and KIT Exon 17 mutants (IC50=0.5 nM) with anticancer activity.
V3474 AZD3229 2248003-60-1 AZD3229 (AZD-3229) is a novel, potent, pan-KIT mutantinhibitor with anticancer activity.
V4154 AZD3229 Tosylate 2248003-71-4 AZD3229 Tosylate, the tosylate salt ofAZD-3229,is a novel, potent, pan-KIT mutantinhibitor with antitumor activity.
V69293 Barzolvolimab (CDX 0159) 2438203-51-9
V69291 Bezuclastinib (CGT9486; PLX 9486) 1616385-51-3
V0631 Dasatinib Monohydrate (BMS354825; Sprycel) 863127-77-9 Dasatinib (formerly BMS-354825; trade name Sprycel), an approved anticancer drug, is an orally bioavailable and multi-targeted kinase inhibitorof Abl, Src and c-Kit with potential anticancer activity.
V3757 DCC-2618 HCl Ripretinib HCl (DCC2618; DCC-2618; Qinlock), the hydrochloride salt of DCC-2618, is an orally bioactive pan KIT and PDGFRA inhibitor approved in 2020 for the treatment of adults with advanced gastrointestinal stromal tumor.
V69295 Elenestinib (BLU-263) 2505078-08-8
V69296 Elenestinib phosphate (BLU-263 phosphate) 2832013-93-9
V0572 Imatinib Mesylate (STI571; Gleevec; Glivec) 220127-57-1 Imatinib Mesylate (also known as STI571 mesylate; trade names: Gleevec or Glivec), the mesylate salt of imatinib, is an orally bioavailable,potent,multi-kinase inhibitor of v-Abl, c-Kit and PDGFR with potential antitumor activity.
V22674 ISCK03 945526-43-2 ISCK03 is a potent c-kit inhibitor.
V69290 Labuxtinib 1426449-01-5
V0630 Pexidartinib (PLX3397; Turalio; CML261; FP113) 1029044-16-3 Pexidartinib (formerly PLX-3397; CML-261;FP-113; trade name Turalio) is an orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor of CSF-1R, Kit, and Flt3 with potential antineoplastic activity.
V13471 Quarfloxin 865311-47-3 Quarfloxin (Quarfloxacin; CX-3543) is a novel and potent fluoroquinolone analoguewith anticancer activity.
V15392 SU14813 627908-92-3 SU14813 is a novel, orally bioavailable, multi-targeted tyrosine kinase inhibitor (TKI) withIC50s of 50, 2, 4, 15 nM forVEGFR2,VEGFR1,PDGFRβandKIT, respectively.
V69294 VEGFR-IN-1 269390-69-4
Contact Us